- Home
- BMRA vs NLSP Comparison
BMRA vs NLSP Comparison
Compare BMRA & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- NLSP
- Stock Information
- Founded
- BMRA 1971
- NLSP 2015
- Country
- BMRA United States
- NLSP Switzerland
- Employees
- BMRA N/A
- NLSP N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- BMRA Health Care
- NLSP Health Care
- Exchange
- BMRA Nasdaq
- NLSP Nasdaq
- Market Cap
- BMRA 5.9M
- NLSP 6.2M
- IPO Year
- BMRA N/A
- NLSP 2021
- Fundamental
- Price
- BMRA $0.64
- NLSP $1.91
- Analyst Decision
- BMRA
- NLSP
- Analyst Count
- BMRA 0
- NLSP 0
- Target Price
- BMRA N/A
- NLSP N/A
- AVG Volume (30 Days)
- BMRA 20.4M
- NLSP 2.2M
- Earning Date
- BMRA 01-14-2025
- NLSP 10-18-2024
- Dividend Yield
- BMRA N/A
- NLSP N/A
- EPS Growth
- BMRA N/A
- NLSP N/A
- EPS
- BMRA N/A
- NLSP N/A
- Revenue
- BMRA $5,578,000.00
- NLSP N/A
- Revenue This Year
- BMRA N/A
- NLSP N/A
- Revenue Next Year
- BMRA N/A
- NLSP N/A
- P/E Ratio
- BMRA N/A
- NLSP N/A
- Revenue Growth
- BMRA 1.40
- NLSP N/A
- 52 Week Low
- BMRA $0.24
- NLSP $1.73
- 52 Week High
- BMRA $1.35
- NLSP $20.80
- Technical
- Relative Strength Index (RSI)
- BMRA 73.05
- NLSP 41.47
- Support Level
- BMRA $0.29
- NLSP $1.87
- Resistance Level
- BMRA $1.27
- NLSP $2.08
- Average True Range (ATR)
- BMRA 0.09
- NLSP 0.27
- MACD
- BMRA 0.04
- NLSP 0.03
- Stochastic Oscillator
- BMRA 36.36
- NLSP 8.77
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.